| Accounting Policies, by Policy (Policies) | 12 Months Ended |
| Dec. 31, 2023 |
| Accounting Policies [Abstract] | |
| Basis of preparation | Basis of preparation The consolidated financial
statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Board (IASB), and International Financial Reporting Interpretations Committee IFRIC interpretations as applicable
to companies reporting under IFRS. These accounts have been prepared under the historical cost convention except for the following items:
- Financial instruments – fair value through profit or loss
- Financial instruments – fair value through other comprehensive income |
| Going Concern | Going Concern The Group incurred losses
during the year and has net assets at the year end. The Group is in the early
stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and
immunology. As the Group is pre-revenue, the Directors expect the Group to incur further losses and to require significant capital expenditure
in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully
funded clinical trials to date and going forward will need to continue to secure additional investment to fund the clinical trials. The Group has experienced net losses and significant cash outflows
from cash used in operating activities over the past years, and as December 31, 2023, had an accumulated loss of $134m and a net loss
for the year ended December 31, 2023 of $17.7m. The Directors have prepared
cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation.
Based on those projections, that the company will not be able to meet its liabilities as they fall due within the next 12 months from
the date when these financial statements are issued. The Directors are however aware, through their own extensive experience in the sector,
that this position is not uncommon in the context of a pre-revenue life sciences company principally involved in cash consuming research
and development activity. The top line data for the
clinical trial is expected in 2025 and the Directors are taking steps to put engagements and plans into place to ensure that sufficient
funds will be forthcoming. These steps include possible deferred payments of existing liabilities, working capital cost reductions and
raising additional equity. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there
is a material uncertainty that may cast significant doubt on the Group and Company’s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this material
uncertainty, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors
are confident, based on the previous fund-raising history as well as additional measures being planned, that sufficient funds will be
forthcoming and accordingly they have prepared these financial statements on a going concern basis. |
| New and Revised Standards | New and Revised Standards Standards in effect in 2023 There are no new IFRS standards,
amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2023, that are relevant to
the Group and that have had any impact in the year to December 31, 2023. New standards, amendments to standards and interpretations that
are not yet effective, which have been deemed by the Group as currently not relevant and are not listed here. |
| Basis of consolidation | Basis of consolidation Subsidiary undertakings are
all entities over which the Group exercises control. The Group has control when it can demonstrate all, of the following: (a) power over
the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power
over the investee to affect the amount of the investor’s return. The existence and effect of
both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether
control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated
from the date at which control ceases. |
| Business combination | Business combination The Group undertook a group
reorganization exercise during the year to December 31, 2021. As part of this process, Tiziana Life Sciences Ltd (a Bermudan entity) was
inserted above Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) in the Group’s structure. As both entities were
under common control of Planwise Ltd, the transaction does not constitute a business combination under IFRS 3 ‘Business combinations’
and instead has been accounted for as a group reorganization, using the pooling of interest method. This results in assets and liabilities
being measured at their carrying amount in Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) but share capital being
that of Tiziana Life Sciences Ltd (a Bermudan entity). Merger accounting has been used to account for this transaction (See note 15 for
details). On 21 October 2021, Tiziana
Life Sciences Ltd. (the ‘Company’) acquired the entire shareholding of the former Tiziana Life Sciences Plc and its related
subsidiaries, by a way of a share for share exchange with Tiziana Life Sciences Ltd becoming the Group’s immediate parent company. On 21 October 2021, the Company
was admitted for listing on the NASDAQ Capital Market Exchange and the former Tiziana Life Sciences Plc was delisted from the London Stock
Exchange. |
| Segment reporting | Segment reporting Operating segments are reported
in a manner consistent with the internal reporting provided to the Board. The Board considers there to be only one operating segment being
the research and development of biotechnological and pharmaceutical products. |
| Taxation | Taxation The tax expense for the year
represents the total of current taxation and deferred taxation. The charge in respect of current taxation is based on the estimated taxable
profit for the year. Current tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been
enacted or substantively enacted by the balance sheet date. Deferred tax is provided in
full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying
amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially
enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the deferred liability is settled.
Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the
temporary differences can be utilized. Research and Development tax
credits are provided for in the year that the costs are incurred. These are estimated based on eligible research and development expenditure.
Any differences that are rebated are recognized in the following year, when the cash is received from the UK tax authorities. |
| Foreign currency translation | Foreign currency translation Items included in the financial
statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity
operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group’s presentational
currency. Foreign currency transactions
are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and
losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary
assets and liabilities denominated in foreign currencies are recognized in the Consolidated statements of operations and comprehensive
loss. The financial statements of
overseas subsidiary undertakings are translated into US dollars on the following basis:
● Assets and liabilities at the rate of exchange ruling at the year-end date.
● Profit and loss account items at the average rate of exchange for the year. Exchange differences arising
from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such
investments, are taken to equity (and recognized in the Consolidated statements of operations and comprehensive loss) on consolidation. |
| License fees | License fees Payments made which provide
the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. “License
fees expenses” are recognized as incurred. |
| Research and development | Research and development All on-going research and
development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the
development of the Group’s products, the criteria for development costs to be recognized as an asset, as set out in IAS 38 ‘Intangible
Assets’, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow
to the Group. The Group currently has no qualifying expenditure. |
| Fair Value Measurement | Fair Value Measurement Management have assessed the
categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined
on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows: Level 1 - valued using quoted prices in active
markets for identical assets Level 2 - valued by reference to valuation techniques
using observable inputs other than quoted prices included within Level 3 - valued by reference to valuation techniques
using inputs that are not based on observable market data. |
| Financial instruments | Financial instruments The Group classifies a financial
instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance
of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument. The Group evaluates the terms
of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified
separately as financial assets, financial liabilities or equity instruments. A financial instrument is
any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. (a) Financial assets, initial
recognition and measurement and subsequent measurement All financial assets not recorded
at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs.
Financial assets carried at fair value through profit or loss (FVTPL) are initially recognized at fair value, and transaction costs are
expensed in the consolidated statements of operations and comprehensive loss. The measurement of financial assets depends on their classification.
Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less
loss allowance. The Group holds an investment in Accustem Inc.as a financial asset at fair value through profit or loss or fair value
through other comprehensive income. (b) Financial liabilities,
initial recognition and measurement and subsequent measurement Financial liabilities are
classified as measured at amortized cost or FVTPL. A financial liability is classified
as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest
expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective
interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition
is also recognized in profit or loss. The Group’s financial
liabilities include trade and other payables. |
| Warrants | Warrants Warrants are issued by the
Group in return for services and as part of a financing transaction. Warrants issued in return for services. These warrants fall within
the scope of IFRS 2. The Company recognizes that the fair value at the date of grant of these warrants should be expensed to the Statement
of Income and recognized over the life of the service for which the warrant was provided. These warrants have been valued by reference
to the equity instruments granted as they are all tied to Convertible loan notes. The measurement date is therefore the date that the
Convertible loan note was entered into. Warrants issued as part of a financing transaction. Warrants issued as part of
a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed amount of cash is
exchanged for a fixed amount of equity. The fair value is recognized within equity and is not remeasured. |
| Share capital | Share capital Ordinary shares of the Company
are classified as equity. |
| Property, plant and equipment | Property, plant and equipment (i Items of property, plant and
equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly
attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized
as part of that equipment. When parts of an item of property,
plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal
of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property,
plant and equipment, and are recognized in profit or loss. (ii) Depreciation Depreciation is calculated
on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value. Depreciation is recognized
in consolidated statements of operations and comprehensive loss on a straight-line basis over the estimated useful life of each part of
an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless
it is reasonably certain that the Group will obtain ownership by the end of the lease term in which case they are depreciated over their
useful lives. The estimated useful lives
for the current period and the comparative period are as follows.
Fixtures and fittings 5 years
IT and equipment 3 years
Right of use asset Economic life of contractual relationship Depreciation methods, useful
lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the Consolidated
statements of operations and comprehensive loss. |
| Impairment | Impairment Impairment of financial assets
measured at amortized cost At each reporting date the
Group recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost. In establishing the appropriate
amount of loss allowance to be recognized, the Group applies either the general approach or the simplified approach, depending on the
nature of the underlying group of financial assets. General approach The general approach is applied
to the impairment assessment of refundable lease deposits and other refundable lease contributions, and cash and cash equivalents. Under the general approach
the Group recognizes a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit
risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognized at an
amount equal to the lifetime expected credit losses. Simplified approach The simplified approach is
applied to the impairment assessment of trade receivables. Under the simplified approach
the Group always recognizes a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses. Impairment of non-financial assets Non-financial assets are tested
for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Non-financial assets are impaired
when carrying amounts exceed recoverable amounts. The recoverable amount is measured as the higher of fair value less cost of disposal
and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present
value at a pre-tax discount rate. |
| Contingent Liabilities | Contingent Liabilities The Company is required to
make judgments about contingent liabilities including the probability of pending and potential future litigation outcomes that, by their
nature, are dependent on future events that are inherently uncertain. In making its determination of possible scenarios, management considers
the evaluation of outside counsel knowledgeable about each matter, as well as known outcomes in case law. |
| Leases | Leases All leases are accounted for
by recognizing a right-of-use asset and a lease liability except for:
● Leases of low value assets; and
● Leases with a duration of 12 months or less. The Group has leases for its
offices. Each lease is reflected on the consolidated balance sheet as a right-of-use asset and a lease liability. The Group does not have
any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage
of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets
in a consistent manner to its property, plant and equipment (see Note 21). For leases over office buildings
and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition
at the end of the lease. The expected costs of returning to its original condition are considered negligible. At the lease commencement
date, the Group recognizes a right-of-use asset and a lease liability in its consolidated balance sheets. The right-of-use asset is measured
at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate
of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement
date (net of any incentives received). At the commencement date,
the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the Group’s
incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible to determine the interest
rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would have to pay to borrow the
same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate is adjusted should the lessee
entity have a different risk profile to that of the Group. The Group depreciates the
right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use
asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist. Lease payments included in
the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index
or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised. Subsequent to initial measurement,
the liability will be reduced by lease payments that are allocated between repayments of principal and finance costs. The finance cost
is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability. Short term leases exempt from
IFRS 16 are classified as operating leases. Payments made under operating leases are recognized in profit and loss on a straight-line
basis over the term of the lease. |
| Share – based payments | Share – based payments The calculation of the fair
value of equity-settled share-based awards and the resulting charge to the Consolidated statements of operations and comprehensive loss
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company’s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of
the awards. Where employees and directors
are rewarded using share-based payments, the fair value of the employees’, directors’ and/or advisers’ services are
determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes
the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets). In accordance with IFRS 2,
a charge is made to the Consolidated statements of operations and comprehensive loss for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to an equity reserve, in the case of options/warrants
awarded to employees, directors, advisers and other consultants. If vesting periods or other
vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share
options/warrants expected to vest. Non- market vesting conditions are included in assumptions about the number of options/warrants that
are expected to become exercisable. Estimates are subsequently
revised, if there is any indication that the number of share options/warrants expected to vest differs from previous estimates. No adjustment
is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised than originally
estimated. Upon exercise of share options/warrants,
the proceeds received are allocated to share capital with any excess being recorded as share premium. A corresponding debit is made to
the share–based payment reserve. Where share options are cancelled,
this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognized for services
received over the remainder of the vesting period is recognized immediately within the Consolidated statements of operations and comprehensive
loss. All goods and services received
in exchange for the grant of any share – based payment are measured at their fair value. |
| Sub license income | Sub license income In September 2021 the Company
signed a collaboration agreement signed with Precision Biosciences, Inc. under which $750k was recognized as an upfront payment in accordance
with the contract for the grant of an exclusive license to use foralumab as a lymphodepletion agent in conjunction with Precision Biosciences,
Inc’s allogeneic CAR T therapeutics for the treatment of cancers. Sublicense income is included in other income on the consolidated
statements of operations and comprehensive loss. |
| Other Intangible Assets | Other intangible assets Other intangible assets that
are acquired by the Group are stated at cost less accumulated impairment losses. At each balance sheet date
non-financial assets are assessed to determine whether there is an indication that the asset or the asset’s cash generating unit
may be impaired. If there is such an indication the recoverable amount of the asset or asset’s cash generating unit is compared
to the carrying amount. |
| Relassification of Prior Year Presentation | Relassification of Prior Year Presentation Certain prior year amounts have been reclassified
for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment
has been made to the consolidated statement of comprehensive income for the year ending December 31, 2022 to reclassify other loss to
finance expense totaling $804k. |
